SV2018005615A - Nueva asociacion entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr - Google Patents
Nueva asociacion entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfrInfo
- Publication number
- SV2018005615A SV2018005615A SV2018005615A SV2018005615A SV2018005615A SV 2018005615 A SV2018005615 A SV 2018005615A SV 2018005615 A SV2018005615 A SV 2018005615A SV 2018005615 A SV2018005615 A SV 2018005615A SV 2018005615 A SV2018005615 A SV 2018005615A
- Authority
- SV
- El Salvador
- Prior art keywords
- morfolinilmetil
- pirrol
- diona
- indol
- oxo
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title abstract 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title 1
- 125000001570 methylene group Chemical class [H]C([H])([*:1])[*:2] 0.000 title 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title 1
- -1 METHYLEN Chemical class 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
ASOCIACIÓN ENTRE LA 3-[(3-{[4-(4-MORFOLINILMETIL)-1H-PIRROL-2-IL]METILEN}-2-OXO-2,3-DIHIDRO-1H-INDOL-5-IL)METIL]-1,3-TIAZOLIDINA-2,4-DIONA DE FÓRMULA (I) (VER FORMULA): O UNO DE SUS ISÓMEROS Z O E Y/O SALES DE ADICIÓN A UN ÁCIDO O A UNA BASE FARMACEUTICAMENTE ACEPTABLE, Y UN INHIBIDOR DE TIROSINA QUINASA DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO HUMANO (EGFR)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1557412A FR3039401B1 (fr) | 2015-07-31 | 2015-07-31 | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2018005615A true SV2018005615A (es) | 2018-05-14 |
Family
ID=55299545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2018005615A SV2018005615A (es) | 2015-07-31 | 2018-01-17 | Nueva asociacion entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr |
Country Status (40)
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101956978B1 (ko) * | 2015-05-18 | 2019-03-12 | 주식회사 케이티 | 시스템 정보 송수신 방법 및 그 장치 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008034776A1 (en) * | 2006-09-18 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
RS52351B (en) * | 2007-03-01 | 2012-12-31 | Novartis Ag | 5- (2,4-Dihydroxy-5-isopropyl-phenyl) -4- (4-morpholine-4-ylmethyl-phenyl) -isoxazole-3-carboxylic acid ethylamide mesylate, their hydrates and polymorphs, and formulations thereof |
CA2680161A1 (en) * | 2007-03-05 | 2008-09-12 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition |
UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
FR2948940B1 (fr) * | 2009-08-04 | 2011-07-22 | Servier Lab | Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP5945863B2 (ja) * | 2012-01-06 | 2016-07-05 | 国立大学法人高知大学 | 腎細胞がん治療剤 |
CN105246511A (zh) * | 2013-03-06 | 2016-01-13 | 豪夫迈·罗氏有限公司 | 治疗和预防癌症药物抗性的方法 |
FR3008411B1 (fr) * | 2013-07-12 | 2015-07-03 | Servier Lab | Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent |
WO2015104043A1 (en) * | 2014-01-07 | 2015-07-16 | Merck Patent Gmbh | Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib |
WO2016055916A1 (en) * | 2014-10-06 | 2016-04-14 | Novartis Ag | Therapeutic combination for the treatment of cancer |
-
2015
- 2015-07-31 FR FR1557412A patent/FR3039401B1/fr not_active Expired - Fee Related
-
2016
- 2016-07-11 SG SG10201605664SA patent/SG10201605664SA/en unknown
- 2016-07-11 PH PH12016000248A patent/PH12016000248A1/en unknown
- 2016-07-20 AU AU2016206300A patent/AU2016206300A1/en not_active Abandoned
- 2016-07-21 CA CA2936904A patent/CA2936904C/fr not_active Expired - Fee Related
- 2016-07-26 US US15/219,691 patent/US20170027952A1/en not_active Abandoned
- 2016-07-27 BR BR102016017404A patent/BR102016017404A2/pt not_active IP Right Cessation
- 2016-07-27 MX MX2016009743A patent/MX366748B/es active IP Right Grant
- 2016-07-28 KR KR1020160096116A patent/KR101822492B1/ko active IP Right Grant
- 2016-07-28 CN CN201610603485.2A patent/CN106397427A/zh active Pending
- 2016-07-29 PE PE2018000094A patent/PE20190350A1/es unknown
- 2016-07-29 CR CR20180044A patent/CR20180044A/es unknown
- 2016-07-29 JP JP2016149874A patent/JP2017061445A/ja active Pending
- 2016-07-29 MA MA39693A patent/MA39693B1/fr unknown
- 2016-07-29 EP EP16181821.6A patent/EP3124025B1/fr active Active
- 2016-07-29 NO NO16181821A patent/NO3124025T3/no unknown
- 2016-07-29 RS RS20180362A patent/RS57057B1/sr unknown
- 2016-07-29 ES ES16181821.6T patent/ES2671133T3/es active Active
- 2016-07-29 EA EA201600507A patent/EA032217B1/ru not_active IP Right Cessation
- 2016-07-29 HU HUE16181821A patent/HUE037632T2/hu unknown
- 2016-07-29 TN TNP/2018/000028A patent/TN2018000028A1/fr unknown
- 2016-07-29 RU RU2016131395A patent/RU2695362C2/ru not_active IP Right Cessation
- 2016-07-29 TW TW105124215A patent/TWI623315B/zh not_active IP Right Cessation
- 2016-07-29 PT PT161818216T patent/PT3124025T/pt unknown
- 2016-07-29 PL PL16181821T patent/PL3124025T3/pl unknown
- 2016-07-29 DK DK16181821.6T patent/DK3124025T3/en active
- 2016-07-29 WO PCT/FR2016/051976 patent/WO2017021634A1/fr active Application Filing
- 2016-07-29 ME MEP-2018-75A patent/ME03052B/me unknown
- 2016-07-29 MD MDE20170007T patent/MD3124025T2/ro not_active IP Right Cessation
- 2016-07-29 SI SI201630028T patent/SI3124025T1/en unknown
- 2016-07-29 CU CUP2018000013A patent/CU20180013A7/es unknown
- 2016-07-29 AR ARP160102311A patent/AR105527A1/es unknown
- 2016-07-29 LT LTEP16181821.6T patent/LT3124025T/lt unknown
-
2018
- 2018-01-17 SV SV2018005615A patent/SV2018005615A/es unknown
- 2018-01-18 EC ECIEPI20183671A patent/ECSP18003671A/es unknown
- 2018-01-29 CL CL2018000256A patent/CL2018000256A1/es unknown
- 2018-01-30 IL IL257232A patent/IL257232A/en unknown
- 2018-01-30 CO CONC2018/0000953A patent/CO2018000953A2/es unknown
- 2018-05-15 CY CY181100494T patent/CY1120792T1/el unknown
- 2018-05-16 HR HRP20180760TT patent/HRP20180760T1/hr unknown
-
2019
- 2019-05-27 JP JP2019098506A patent/JP2019163306A/ja not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1125110T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
UY35998A (es) | 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA | |
AR095039A1 (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
IL279910A (en) | Crystal forms of 5-chloro-ene 4-[2-(dimethylphosphoryl)phenyl]-ene 2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidin-2- 4-diamine | |
CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
CO2017002532A2 (es) | Indazoles sustituidos con bencilo como inhibidores de bub1 | |
BR112018002071A2 (pt) | compostos heteroarílicos ou arílicos fundidos bicíclicos | |
EA201891917A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
DOP2015000308A (es) | Inhibidores de bromodominios | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
UY35798A (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos | |
DOP2015000197A (es) | Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad agonista del receptor ¿2 adrenérgico así como actividad antagonista del receptor muscarínico m3. | |
MX2016014904A (es) | Sales de adicion de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)e til)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-car bonitrilo. | |
SMT201600078B (it) | Antagonista del recettore per cgrp | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
UY36110A (es) | Inhibidores de quinasa relacionados con tropomiosina | |
MA40250A (fr) | Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k | |
ECSP18009366A (es) | Antagonistas del receptor de cgrp | |
EA201590823A1 (ru) | 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора | |
NI201300125A (es) | Derivados de 2 - amino - 3 - ( imidazol - 2 - il ) - piridin - 4 - ona y su uso como inhibidores de cinasa del receptor vegf. | |
AU2015292632B2 (en) | Aldosterone synthase inhibitors | |
AR092772A1 (es) | Derivado de 7-azaindol | |
SV2018005615A (es) | Nueva asociacion entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr | |
CR20160373A (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina | |
UY34316A (es) | Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad |